Selected for the Physician-Scientist Training Program—Third Consecutive Selection

500 Million KRW Over Three Years—Supporting Resident Research and Infrastructure Development

[April 11, 2025]

Yeungnam University (President CHOI Oe-chool) has been selected as a final recipient of the 2025 Convergence-Type Physician-Scientist Training Program (Undergraduate and Graduate Infrastructure), jointly announced by the Ministry of Health and Welfare and the Korea Health Industry Development Institute. As part of a consortium led by Korea University and joined by Hanyang University and Chungbuk National University, YU’s College of Medicine will receive approximately 500 million KRW in funding over three years, through February 2028, to support physician-scientist training initiatives.

 A physician-scientist is a researcher who studies diseases based on knowledge of both clinical and basic medicine. Since 2019, the Ministry of Health and Welfare has supported the full-cycle training of physician-scientists through this program, aiming to cultivate talent that meets global standards. 

YU's College of Medicine has participated in the program since its inception in 2019, contributing to the development of physician-scientist training systems and collaborative education and research platforms within the consortium. In this third phase of the program, the university will focus on supporting research for medical residents and strengthening infrastructure. The goals include establishing a foundation for interdisciplinary research and education, expanding training programs for resident physician-scientists, and formulating strategies for utilizing and supporting these professionals post-graduation.

KWON Gyu-jang, Dean of the YU College of Medicine, stated, “Being selected for this program for the third consecutive time allows us to ensure continuity and chart a long-term path for development. Based on YU’s educational and research infrastructure, we will deliver an optimized physician-scientist training program that contributes to the growth of the biomedical industry.”